| Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer MM Noblejas-López, C Nieto-Jimenez, M Burgos, M Gómez-Juárez, ... Journal of Experimental & Clinical Cancer Research 38, 1-9, 2019 | 83 | 2019 |
| Controlled delivery of BET-PROTACs: in vitro evaluation of MZ1-loaded polymeric antibody conjugated nanoparticles in breast cancer FJ Cimas, E Niza, A Juan, MM Noblejas-López, I Bravo, A Lara-Sanchez, ... Pharmaceutics 12 (10), 986, 2020 | 47 | 2020 |
| Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome MM Noblejas-López, C Nieto-Jiménez, S Morcillo Garcia, J Pérez-Peña, ... Oncoimmunology 8 (10), e1629780, 2019 | 46 | 2019 |
| Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of dasatinib in HER2+ metastasic breast cancer E Niza, MM Noblejas-López, I Bravo, C Nieto-Jiménez, JA Castro-Osma, ... Nanomaterials 9 (12), 1793, 2019 | 42 | 2019 |
| Poly (cyclohexene phthalate) nanoparticles for controlled dasatinib delivery in breast cancer therapy E Niza, C Nieto-Jiménez, MM Noblejas-López, I Bravo, JA Castro-Osma, ... Nanomaterials 9 (9), 1208, 2019 | 27 | 2019 |
| Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene MM Noblejas-López, S Morcillo-Garcia, C Nieto-Jiménez, ... PLoS One 13 (11), e0207776, 2018 | 19 | 2018 |
| Options to improve the action of PROTACs in cancer: development of controlled delivery nanoparticles A Juan, MM Noblejas-López, M Arenas-Moreira, C Alonso-Moreno, ... Frontiers in Cell and Developmental Biology, 3912, 2021 | 18 | 2021 |
| Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors S Morcillo-Garcia, MM Noblejas-Lopez, C Nieto-Jimenez, J Perez-Peña, ... PLoS One 14 (4), e0209134, 2019 | 18 | 2019 |
| Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer C Nieto-Jimenez, EM Galan-Moya, V Corrales-Sanchez, ... Cancer letters 491, 50-59, 2020 | 17 | 2020 |
| Mapping of genomic vulnerabilities in the post-translational ubiquitination, SUMOylation and neddylation machinery in breast cancer J Fuentes-Antrás, AL Alcaraz-Sanabria, EC Morafraile, ... Cancers 13 (4), 833, 2021 | 15 | 2021 |
| Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer V Corrales‐Sánchez, MM Noblejas‐López, C Nieto‐Jiménez, ... Journal of Cellular and Molecular Medicine 24 (5), 3117-3127, 2020 | 13 | 2020 |
| MZ1 co-operates with trastuzumab in HER2 positive breast cancer MM Noblejas-López, C Nieto-Jiménez, EM Galán-Moya, D Tebar-García, ... Journal of Experimental & Clinical Cancer Research 40, 1-12, 2021 | 10 | 2021 |
| Antitumoral activity of a CDK9 PROTAC compound in HER2-positive breast cancer MM Noblejas-López, L Gandullo-Sánchez, EM Galán-Moya, ... International Journal of Molecular Sciences 23 (10), 5476, 2022 | 9 | 2022 |
| Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer MM Noblejas-López, I López-Cade, J Fuentes-Antrás, ... Cancers 13 (16), 4118, 2021 | 7 | 2021 |
| Enhanced antitumoral activity of encapsulated BET inhibitors when combined with PARP inhibitors for the treatment of triple-negative breast and ovarian cancers A Juan, MM Noblejas-López, I Bravo, M Arenas-Moreira, ... Cancers 14 (18), 4474, 2022 | 4 | 2022 |
| TACkling Cancer by Targeting Selective Protein Degradation MM Noblejas-López, D Tébar-García, R López-Rosa, A Alcaraz-Sanabria, ... Pharmaceutics 15 (10), 2442, 2023 | 3 | 2023 |
| Transcriptomic profiles of CD47 in breast tumors predict outcome and are associated with immune activation MM Noblejas-López, M Baliu-Piqué, C Nieto-Jiménez, FJ Cimas, ... International Journal of Molecular Sciences 22 (8), 3836, 2021 | 2 | 2021 |
| T-reg transcriptomic signatures identify response to check-point inhibitors MM Noblejas-López, E García-Gil, P Pérez-Segura, A Pandiella, B Győrffy, ... Scientific Reports 14 (1), 10396, 2024 | | 2024 |
